Evaluate the regulatory effects of Salecan (ß-1,3/a-1,3 glucan) on blood glucose, blood lipids, blood pressure, obesity, visceral fat, uric acid, fatty liver, immune function, inflammation, oxidative stress, and intestinal flora, while investigating its efficacy in alleviating symptoms of chronic diseases such as rhinitis and inflammatory bowel disease (IBD).
Conditions
Interventions
Control group:None
Intervention group:Oral Salecan
Sponsors
The First People's Hospital of Qinzhou
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18 to 75 years old (inclusive); 2.Able to understand and willing to strictly follow the research protocol to complete the trial, and has signed the informed consent form; 3.No congenital, neurological or psychiatric diseases (such as congenital heart disease, paralysis, deaf-mutism, dementia, mental disorders).
Exclusion criteria
Exclusion criteria: 1.Pregnant or lactating women; 2.Complicated with severe cardiac, hepatic or renal insufficiency, including but not limited to ALT and/or AST >= 2×ULN, serum creatinine >= 1.5×ULN, eGFR < 60 ml/(min×1.73m^2); 3.Complicated with severe organic diseases such as heart, liver, lung, brain diseases, or autoimmune diseases, malignant tumors; 4.Recent surgery, or receiving immunotherapy or other biological agents.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Twelve items of cytokines;Visceral fat;Immunoglobulin;Blood lipid;VAS;Erythrocyte sedimentation rate (ESR);Key indicators for blood glucose control;Inhalation and food allergen antibody determination IgE (20 tests);CRP;TNSS;Oxidative Stress; | — |
Secondary
| Measure | Time frame |
|---|---|
| TOSS;Gut microbiota;Rhinitis Control Assessment Test;Blood routine;Liver function;Renal function;Urinalysis; | — |
Countries
China
Contacts
Public ContactYuanli Wang
The First People's Hospital of Qinzhou
Outcome results
None listed